Sickle cell disease research has increased over the years, and this research has allowed physicians to effectively treat patients with new treatments. Research has opened the doors to many options for people with sickle cell disease to help them live healthier, happier, lives.

Some of the clinical trials that we are currently participating in are:

  1. A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises.

    Sponsor: Selexys Pharmaceuticals Corporation
    This randomized, placebo-controlled, double-blind study is being conducted to determine the efficacy and safety of SelG1 when administered once every 4 weeks for 52 weeks to patients with a diagnosis of sickle cell disease who may or may not be receiving hydroxyurea and have experienced between 2 and 10 pain crisis in the 12 months preceding enrollment in this study.
  2. Protocol H7T-MC-TADO: A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients with Sickle Cell Disease

    Sponsor: Eli Lilly and Company
    The primary objective of this study is to assess the efficacy of prasugrel compared to placebo in pediatric patients with sickle-cell disease as measured by reduction in the rate of vaso-occlusive crisis. A vaso-occulusive crisis is defined as an onset of moderate to severe pain that lasts at least 2 hours for which there is no explanation other than vaso-occlusion and which requires therapy with oral or parenteral opioids, ketorolac, or other analgesics prescribed by a health care professional in a medical setting such as a hospital, clinic, or emergency room visit.
  3. An Open-label, Multicenter Study of the Safety, Pharmacokinetics, and Efficacy of Buprenorphine Transdermal System (BTDS) in Children From 7 to 16 Years of Age, Inclusive, Who Require Continuous Opioid Analgesia for Moderate to Severe Pain

    Sponsor: Purdue Pharma
    This is an open-label, multicenter, multiple dose study of the safety and efficacy of BTDS in patients, aged 7 to 16 years, inclusive, who require continuous opioid analgesia for moderate to severe pain. Approximately 40 patients will be evaluated for up to 28 weeks, including treatment with BTDS for a minimum of 2 weeks and up to 24 weeks.
  4. A 5-year, Prospective, Non-Interventional, Multicenter Registry in Sickle Cell Disease Patients

    Sponsor: Novartis
    A long-term observational study, to collect data on sickle cell disease patients in the United States in order to enhance the understanding of the disease patterns, current transfusion practices, treatments and outcomes in sickle cell disease.
  5. A Phase III, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of L Glutamine Therapy for Sickle Cell Anemia and Sickle ß0-Thalassemia (Emmaus Medical Inc., Protocol GLUSCC09-01)

    Sponsor: Emmaus Medical, Inc.
    A study to evaluate the efficacy of oral L-glutamine, as a therapy for sickle cell anemia and sickle o-thalassemia as evaluated by the number of occurrences of sickle cell crises.
  6. PFAST: Patent Foramen Ovale and Stroke

    Sponsor: Doris Duke Charitable Foundation (DDCF)
    A multicenter controlled study to compare the prevalence of patent foramen ovale (PFO) or other potential intracardiac shunts detectible by transthoracic echocardiography (TTE) by conventional 2-D, color Doppler, and agitated saline-contrast studies in children with sickle cell disease and stroke to a control group of patients without sickle cell disease or stroke.


1430 Tulane Ave, New Orleans, LA 70112 504-988-5331